Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report
- PMID: 1775604
Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report
Abstract
Recent studies in major depression suggest that a pretreatment systolic orthostatic blood pressure (PSOP) fall of greater than or equal to 10 mm Hg in response to changing from a supine to a standing position may predict response to antidepressant treatment in older depressed patients. Because orthostatic blood pressure response is regulated, in part, by central cholinergic and noradrenergic systems, and both are implicated in Alzheimer's disease, PSOP was assessed as a predictor of initial response in Alzheimer's disease outpatients in a treatment protocol with tacrine, a cholinesterase inhibitor. We found that the magnitude of PSOP fall and increasing age each contributed to the prediction of response to tacrine. These results may suggest a relatively greater involvement of other neurotransmitter systems in younger, nonresponding Alzheimer's disease patients, and the results differ from those of a previous study.
Similar articles
-
Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.Psychopharmacol Bull. 1991;27(3):301-7. Psychopharmacol Bull. 1991. PMID: 1775603 Clinical Trial.
-
Pretreatment orthostatic hypotension as a predictor of response to nortriptyline in geriatric depression.J Clin Psychopharmacol. 1986 Jun;6(3):172-6. J Clin Psychopharmacol. 1986. PMID: 3711368 Clinical Trial.
-
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.Arch Intern Med. 1995 Sep 11;155(16):1766-72. Arch Intern Med. 1995. PMID: 7654110 Clinical Trial.
-
Tacrine therapy for the dementia of Alzheimer's disease.Am Fam Physician. 1994 Sep 15;50(4):819-26. Am Fam Physician. 1994. PMID: 8079912 Review.
-
[Tacrine in Alzheimer's disease].Rev Neurol. 1997 Jul;25 Suppl 1:S70-2. Rev Neurol. 1997. PMID: 9280671 Review. Spanish. No abstract available.
Cited by
-
Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement.Curr Alzheimer Res. 2018;15(10):905-916. doi: 10.2174/1567205015666180507105326. Curr Alzheimer Res. 2018. PMID: 29732972 Free PMC article.
-
Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.Drugs Aging. 1994 Jun;4(6):510-40. doi: 10.2165/00002512-199404060-00006. Drugs Aging. 1994. PMID: 7521234 Review.
-
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.Br J Clin Pharmacol. 2022 Jun;88(6):2814-2829. doi: 10.1111/bcp.15206. Epub 2022 Jan 26. Br J Clin Pharmacol. 2022. PMID: 34964149 Free PMC article. Clinical Trial.
-
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.J Psychiatry Neurosci. 2003 Jan;28(1):13-26. J Psychiatry Neurosci. 2003. PMID: 12587847 Free PMC article. Review.
-
Functional imaging of the brain in the evaluation of drug response and its application to the study of aging.Drugs Aging. 1998 Sep;13(3):211-22. doi: 10.2165/00002512-199813030-00004. Drugs Aging. 1998. PMID: 9789725 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical